13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
46 檔
64.5%
According to the latest 13F quarterly dataset, Artia Global Partners LP managed an equity portfolio of $541.9M at the end of Q2 2024, spanning 46 distinct U.S. exchange-listed positions.
During Q2 2024, Artia Global Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 19.09% | — | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 16.20% | -7.04% | EXIT | |
| 3 | ✓ | Eli Lilly & Co | Stock-Other | 13.13% | — | -34.78% | |
| 4 | MRK | Merck & Co. Inc. | Stock-Healthcare | 10.59% | -0.01% | +16.69% | |
| 5 | NVO | Novo Nordisk A/S | Stock-Healthcare | 8.55% | — | — | |
| 6 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 4.64% | +0.12% | +4.47% | |
| 7 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.88% | — | — | |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.87% | — | +3.06% | |
| 9 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.71% | — | -34.60% | |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.64% | — | — | |
| 11 | ✓ | Viking Therapeutics Inc | Stock-Other | 1.54% | — | — | |
| 12 | ✓ | Insmed Inc | Stock-Other | 1.42% | — | — | |
| 13 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.37% | — | — | |
| 14 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.26% | +0.74% | -55.79% | |
| 15 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.20% | — | — | |
| 16 | PCVX | Vaxcyte Inc | Stock-Other | 1.11% | — | — | |
| 17 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.83% | +0.04% | — | |
| 18 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 19 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.74% | -0.46% | EXIT | |
| 20 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.74% | — | — | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 0.69% | -18.15% | -54.81% | |
| 22 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.66% | — | -31.00% | |
| 23 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.58% | -0.06% | — | |
| 24 | ✓ | Merus N V | Stock-Other | 0.57% | — | — | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.54% | — | — | |
| 26 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.44% | -0.10% | EXIT | |
| 27 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 28 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.37% | — | +3.62% | |
| 29 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.37% | — | — | |
| 30 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.30% | -0.04% | — | |
| 31 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.29% | — | — | |
| 32 | CRL | Charles River Laboratories | Stock-Healthcare | 0.28% | — | — | |
| 33 | KURA | Kura Oncology Inc | Stock-Other | 0.23% | — | +44.84% | |
| 34 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.20% | -0.08% | — | |
| 35 | ASND | Ascendis Pharma A/S | Stock-Other | 0.20% | -0.81% | EXIT | |
| 36 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.19% | — | — | |
| 37 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.19% | — | — | |
| 38 | KROS | Keros Therapeutics Inc | Stock-Other | 0.18% | — | — | |
| 39 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.17% | — | — | |
| 40 | EYPT | Eyepoint Inc | Stock-Other | 0.17% | +0.04% | +97.09% | |
| 41 | ANNX | Annexon Inc | Stock-Other | 0.14% | — | — | |
| 42 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.13% | — | +55.51% | |
| 43 | IRON | Disc Medicine Inc | Stock-Other | 0.12% | — | -84.56% | |
| 44 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.10% | — | -50.00% | |
| 45 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.08% | — | — | |
| 46 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.08% | — | — |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 46 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NVO, LLY, ELI LILLY & CO) accounted for 64.5% of total reported equity market value during Q2 2024.
During Q2 2024, Artia Global Partners LP's top holdings by market value included NVO (19.1%)、LLY (16.2%)、ELI LILLY & CO (13.1%). The largest single position, NVO, represented 19.1% of total portfolio value.
In Q2 2024, Artia Global Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.